Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $11,171,994.40 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 426,412 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $26.20, for a total transaction of $11,171,994.40. Following the completion of the sale, the director owned 751,411 shares in the company, valued at $19,686,968.20. This represents a 36.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Up 3.0%

Shares of Dyne Therapeutics stock opened at $26.78 on Thursday. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. The company has a market cap of $5.00 billion, a P/E ratio of -8.04 and a beta of 1.07. The firm’s 50 day moving average price is $23.36 and its 200-day moving average price is $19.67. Dyne Therapeutics, Inc. has a 52-week low of $11.65 and a 52-week high of $27.31.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.47 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on DYN. Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. TD Cowen assumed coverage on Dyne Therapeutics in a research report on Friday, June 26th. They set a “buy” rating on the stock. Cantor Fitzgerald began coverage on Dyne Therapeutics in a research report on Thursday, July 23rd. They set an “overweight” rating on the stock. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a report on Friday, May 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.42.

More Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $50 price target for Dyne, well above the stock’s recent trading level. The firm’s long-term model still projects a shift from losses to profitability, with estimated EPS of $1.28 in fiscal 2030.
• Neutral Sentiment: Dyne’s strong balance-sheet liquidity remains a supporting factor, with a quick ratio of approximately 12 and relatively low debt compared with equity. Institutional investors also own about 96.7% of the shares, indicating substantial professional-investor participation.
• Negative Sentiment: HC Wainwright significantly reduced its EPS forecasts across 2026–2030. Estimates were lowered to losses of $0.98 per share for Q3 2026, $1.01 for Q4, $3.82 for full-year 2026, $3.28 for 2027, $1.91 for 2028 and $0.49 for 2029. Its 2030 profit estimate was also cut to $1.28 from $2.26, signaling expectations for a slower path to profitability.
• Negative Sentiment: Director Jason Rhodes sold 426,412 shares at an average price of $26.20, worth approximately $11.2 million, reducing his direct ownership by 36.2%. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which may reduce its significance as a discretionary bearish signal, but the transaction can still pressure sentiment.
• Negative Sentiment: Dyne previously reported quarterly EPS of negative $1.08, missing the consensus estimate of negative $0.75. The company remains a clinical-stage biotechnology business with no established commercial revenue base, making future stock performance highly dependent on clinical progress and funding expectations.

Institutional Trading of Dyne Therapeutics

Several large investors have recently made changes to their positions in DYN. AQR Capital Management LLC acquired a new position in Dyne Therapeutics in the 1st quarter valued at $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Dyne Therapeutics by 5.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after purchasing an additional 2,886 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Dyne Therapeutics by 58.2% during the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after buying an additional 366,183 shares in the last quarter. Caxton Associates LLP purchased a new stake in shares of Dyne Therapeutics during the first quarter worth $157,000. Finally, Creative Planning raised its position in shares of Dyne Therapeutics by 23.8% in the second quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after buying an additional 2,797 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.